Immunomedics (NASDAQ:IMMU) is scheduled to be issuing its quarterly earnings data after the market closes on Wednesday, August 7th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
Immunomedics (NASDAQ:IMMU) last issued its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.36) by ($0.10). During the same period last year, the company posted ($0.21) earnings per share. On average, analysts expect Immunomedics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
Immunomedics stock traded down $0.50 during mid-day trading on Monday, reaching $13.32. 23,656 shares of the company’s stock were exchanged, compared to its average volume of 1,573,118. The business has a fifty day simple moving average of $14.17. The company has a market capitalization of $2.65 billion, a price-to-earnings ratio of -13.02 and a beta of 1.98. Immunomedics has a one year low of $11.55 and a one year high of $26.99. The company has a debt-to-equity ratio of 0.04, a current ratio of 7.89 and a quick ratio of 7.89.
In related news, insider Avoro Capital Advisors Llc acquired 750,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The shares were bought at an average cost of $15.11 per share, for a total transaction of $11,332,500.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Bryan Ball acquired 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 20th. The shares were bought at an average price of $13.35 per share, for a total transaction of $66,750.00. Following the completion of the purchase, the insider now owns 5,000 shares in the company, valued at approximately $66,750. The disclosure for this purchase can be found here. Over the last 90 days, insiders acquired 4,976,078 shares of company stock worth $66,108,902. Corporate insiders own 9.40% of the company’s stock.
IMMU has been the topic of a number of recent analyst reports. Cowen set a $30.00 price target on Immunomedics and gave the stock a “buy” rating in a report on Wednesday, July 31st. Zacks Investment Research upgraded Immunomedics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 16th. HC Wainwright restated a “buy” rating and issued a $28.00 target price on shares of Immunomedics in a research note on Monday, May 13th. ValuEngine upgraded Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, Piper Jaffray Companies set a $20.00 target price on Immunomedics and gave the company a “buy” rating in a research note on Monday, April 8th. Three analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the company. Immunomedics has an average rating of “Buy” and a consensus price target of $28.45.
Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.
Further Reading: Consumer behavior in bull markets
Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.